Skip to main content
  • FDA Gives Update on Sartan Impurity Probe

    Probe of poor manufacturing practices now extends beyond ARBs

    The FDA continues to recall angiotensin II receptor blocker (ARB) medications for nitrosamine contamination but, in a statement issued Wednesday morning, offered assurance that it is tackling the manufacturing practices underlying the problem.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details